Developing small molecules to treat leishmaniasis
Targeting the Genus Leishmania with Small Molecules
This study is looking for new, safer medicines to help people with leishmaniasis, a disease caused by parasites from sandflies, by testing different small compounds that can fight the parasites without causing too many side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11036298 on NIH RePORTER |
What this research studies
This research focuses on finding new small molecule treatments for leishmaniasis, a disease caused by parasites transmitted by sandflies. The project aims to identify compounds that can effectively target the Leishmania parasites while minimizing harmful side effects associated with current treatments. By exploring various chemical analogs and their effects on the parasites, the research seeks to improve treatment options for patients suffering from this neglected disease. The study also considers the immune response of patients, which can influence treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with leishmaniasis, particularly those experiencing severe symptoms or adverse effects from current treatments.
Not a fit: Patients with leishmaniasis who are already responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for leishmaniasis, improving patient outcomes and quality of life.
How similar studies have performed: Previous research has shown promise in developing new treatments for leishmaniasis, but this approach is innovative and aims to address the limitations of current therapies.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Schaus, Scott Edward — Boston University (Charles River Campus)
- Study coordinator: Schaus, Scott Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.